07:39 AM EDT, 06/26/2025 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Thursday that it has received a Special Protocol Assessment agreement letter from the US Food and Drug Administration for a clinical trial of ADX-2191 in primary vitreoretinal lymphoma, a rare and potentially fatal cancer.

The proposed clinical trial under the Special Protocol Assessment will compare cancer cell clearance after 30 days of therapy in up to 20 patients following either a single intraocular injection or eight intraocular injections, Aldeyra said.

The trial is expected to begin in H2 and be completed in 2026, the company said.

Shares of Aldeyra Therapeutics ( ALDX ) were up 2.3% in recent premarket activity.